Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
Zacks.com on MSN2d
GSK Meets Study Goal for Co-Administered RSV-Shingles VaccinesGSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...
Venturi Cardiology, a leading, state of the art cardiology clinic in North West England offering rapid access to clinical ...
FeedbackNow, the world leader in operational analytics for physical spaces, announced today their Series A round. The round was led by Motivate VC, Uncorrelated Ventures, and AI Growth Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback